

Patrick Marroum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10213713/publications.pdf>

Version: 2024-02-01

10
papers

337
citations

1307594

7
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

363
citing authors

#	ARTICLE	IF	CITATIONS
1	Utility of Modeling and Simulation Approach to Support the Clinical Relevance of Dissolution Specifications: a Case Study from Upadacitinib Development. AAPS Journal, 2022, 24, 39.	4.4	2
2	Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure. Biopharmaceutics and Drug Disposition, 2022, 43, 98-107.	1.9	4
3	Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation. AAPS Journal, 2019, 21, 108.	4.4	15
4	Developing Quantitative In Vitro-In Vivo Correlation for Fenofibrate Immediate-Release Formulations With the Biphasic Dissolution-Partition Test Method. Journal of Pharmaceutical Sciences, 2018, 107, 476-487.	3.3	32
5	Development of In Vitro-In Vivo Correlation for Potassium Chloride Extended Release Tablet Formulation Using Urinary Pharmacokinetic Data. Pharmaceutical Research, 2017, 34, 1527-1533.	3.5	4
6	In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance. Molecular Pharmaceutics, 2017, 14, 3801-3814.	4.6	44
7	Analysis of level A <i>in vitro</i> - <i>in vivo</i> correlations for an extended-release formulation with limited bioavailability. Biopharmaceutics and Drug Disposition, 2013, 34, 262-277.	1.9	17
8	In Vivo Bioequivalence and In Vitro Similarity Factor (f ₂) for Dissolution Profile Comparisons of Extended Release Formulations: How and When Do They Match?. Pharmaceutical Research, 2011, 28, 1144-1156.	3.5	45
9	Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation. Pharmaceutical Research, 1998, 15, 466-473.	3.5	65
10	Draft Guidance for Industry Extended-Release Solid Oral Dosage Forms. Advances in Experimental Medicine and Biology, 1997, 423, 269-288.	1.6	109